| |
GAITHERSBURG, Md., Nov. 2, 2023 /PRNewswire/ --Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023. Details of the event and replay are as follows:
|
Conference call details:
|
|
|
Date:
|
November 9, 2023
|
|
Time:
|
8:30 a.m. U.S. EST
|
|
Dial-in number:
|
(877) 550-1858 (Domestic) or (848) 488-9160 (International)
|
|
Passcode:
|
1754341
|
|
Webcast:
|
ir.novavax.com/events
|
- Participants will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
|
Replay details:
|
|
|
Date:
|
Available starting at 11:30 a.m. EST, November 9, 2023, until
11:59 p.m. U.S. EST, November 16, 2023
|
|
Dial-in number:
|
(800) 645-7964 (Domestic) or (757) 849-6722 (International)
|
|
Passcode:
|
5567#
|
|
Webcast:
|
ir.novavax.com/events, until February 7, 2024
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
 View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2023-financial-results-and-operational-highlights-on-november-9-2023-301974716.html
SOURCE NOVAVAX, INC
|
|
